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Papillary (PTC) and follicular thyroid carcinomas (FTC) are
usually well differentiated, maintaining in part the characteris-
tics of follicular thyroid cells, including expression of thyroid
cell-specific antigens such as thyroid peroxidase (TPO), the
membrane-bound enzyme essential for the biosynthesis of thyroid
hormone. Recently, TPO gene and protein expression in thyroid
carcinoma has been analysed, with results indicating low enzy-
matic activity (Valenta et al, 1973; Valenta, 1976; Fragu and Nataf,
1977; Mizukami and Matsunaga, 1981), and impaired solubility
(Neary et al, 1978). Mutated TPO genes were found in some
differentiated thyroid carcinomas (Smanik et al, 1994). Although
the expression of TPO mRNA was found to be the same in
cancerous and benign tissue in one study (Ohta et al, 1991), others
have shown suppression of TPO gene expression (Hoang-Vu et al,
1992; Fabbro et al, 1994; Tanaka et al, 1996; Umeki et al, 1996). 
Some differences in the results of experiments using TPO
murine monoclonal antibodies to detect protein expression may
be due to methodological approaches (Yamashita et al, 1993;
Mizukami et al, 1994; Tanaka et al, 1996; Umeki et al, 1996).
However, differential immunohistochemical labelling of TPO with
one monoclonal antibody (mAb#47) was proposed by De Micco
et al (1991) as a marker distinguishing between benign and malig-
nant thyroid tumours, including both PTC and FTC. Reduced
immunostaining with mAb#47 was observed in more than 95% of
malignant thyroid cancers suggesting that abnormal TPO
immunoreactivity occurs in malignancy (DeMicco et al, 1991,
1994). MAb #47 is one of a panel of well characterized murine
monoclonal antibodies produced against native human TPO. The
immunochemical properties of these mAbs have been published
elsewhere (Ruf et al, 1989). 
In order to clarify whether TPO in thyroid cancers is indeed
qualitatively different from TPO in non-cancerous tissues, we
analysed the reactivity of TPO from thyroid cancers with a panel
of murine monoclonal antibodies (including mAb#47) and previ-
ously described human monoclonal anti-TPO IgGκ Fab fragments
(McIntosh et al, 1997). Both types of antibodies react with epitopes
delineating the immunodominant region of TPO (Figure 1). 
METHODS 
Thyroid tissues 
We studied 30 malignant thyroid tumours, 23 of them paired with
corresponding normal tissue obtained from adjacent parts of the
gland. Thyroid tissues were obtained from patients undergoing
surgery for thyroid cancer by the Institute of Oncology, Gliwice,
Poland. Tissues fragments were immediately frozen in liquid N2,
and kept at –80˚C until use. Tumours were diagnosed histopatho-
logically according to World Health Organization (WHO) criteria:
3 cases were follicular carcinomas (FTC) and 27 cases were papil-
lary carcinomas (PTC). 10 thyroid samples from patients with
Graves’ disease were also included in the study. Details of the
patients are summarized in Table 1. The local Committees on
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written consent. 
Murine mAb and human recombinant IgGκ antibodies 
A panel of 12 murine anti-TPO monoclonal antibodies (mAb),
previously produced and characterized, directed to epitopes from 3
antigenic domains of TPO was used (Ruf et al, 1989). Antibodies
mAb#2, #9, #47, #60 – recognize domain A; mAb#15, #18, #59,
#64 – domain B, and mAb#1, #30, #40, #53 – domain D. Domains
A and B, defining the immunodominant region of TPO, are adja-
cent whereas domain D is topologically distant. Characterization
of the human Fabs has been described elsewhere (Czarnocka et al,
1997; McIntosh et al, 1997). In this study, Fabs representative for
domain A (126 TP1, 6, 7, 8, 10 and 126 TO 10), and domain B
reactivity (126 TP5, 9, 13, 14, 15 and 126 TO1) were used. All
experiments were carried out on Fab prepared in culture medium. 
Thyroid microsomes preparation and solubilization 
Thyroid microsomes were prepared and solubilized as previously
described (Czarnocka et al, 1985). Briefly, the thyroid tissues
were homogenized in 10 mM Tris-HCl buffer pH 7.5, containing 
2 µ g ml–1 aprotinin, 1 µ g ml–1 leupeptin, 1 µ g ml–1 pepstatin and
0.1 mM phenylmethylsulfonyl fluoride (all from Boehringher
Mannheim, Mannheim, Germany). The plasma membranes were
pelleted by centrifugation at 10 000 g for 15 min at 4˚C and the
supernatants were subsequently ultracentrifuged at 100 000 g for
60 min at 4˚C. The resulting membrane fractions were solubilized
with sodium deoxycholate, and stored at –80˚C until use. The
protein concentration was determined by the BCA micro-method
(Pierce Chemical Co, Rockford, IL, USA). 
TPO capture method 
The antigen capture method was used to detect solubilized TPO.
Maxisorb microtitre plates (Nunc, Copenhagen, Denmark) were
coated with 100 µ l of mAb solution diluted to 10 µ g ml–1 in 0.1 M
carbonate buffer pH 9.6, overnight at 4˚C under a humidified
atmosphere. The wells were then washed, blocked with BSA,
washed again, and filled with 100 µ l of solubilizate adjusted to 20
µ g ml–1 in PBS pH 7.8, containing 0.1% of Tween-20 and 3 mM
sodium azide. After overnight incubation at 4˚C, unbound protein
was removed by extensive washing and wells filled with 100 µ l of
Fab diluted 1:15 with PBS-Tween-20-azide. After 12 h at 4˚C,
unbound antibodies were removed by extensive washing. Fab
binding was detected using an immunoaffinity-purified antihuman
Fab second antibody labelled with horseradish peroxidase
(Jackson ImmunoResearch Laboratories, Inc, West Grove, PA,
USA); tetramethyl benzidine was the substrate. Absorbance was
read at 450 nm. 
SDS-PAGE and Western blot 
Thyroid microsomes as well as their solubilizates were diluted with
buffer containing 0.125 M Tris-HCl pH 6.8, 10% β -mercaptoethanol,
4% SDS, and 20% glycerol, to a concentration of 1 mg ml–1, boiled
and loaded (20 µ g lane–1) onto 10% SDS polyacrylamide mini
gels. Non-denaturing sample buffer consisted of 0.3125 M Tris,
0.5 M dithiothreitol, 1.5% SDS and 50% glycerol and microsomes
or solubilizates were diluted to 1 mg ml–1 with the above buffer
and incubated for 30 min at 37˚C and loaded (20 µ g lane–1) onto
SDS polyacrylamide mini gels, 0.75 mm thick. Proteins were
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Figure 1 Map of the epitopes on thyroid peroxidase (TPO) recognized by
































Table 1 Clinical data 
Patient no Sex/age (y) Histology pTNM  TSH 
1 M/54 PTC + NT T3a NA 
2 F/65 FTC + NT NA 0,15 
3 F/43 PTC + NT T2 3,43 
4 F/60 FTC + NT T2b 4,88 
5 F/50 PTC + NT T2 1,12 
6 M/45 PTC T2b; N1 NA 
7 F/64 PTC T3 NA 
8 F/24 PTC + NT T2b;; N1 0,7 
9 F/65 PTC + NT NA NA 
10 F/46 PTC + NT T1a 0,4 
11 F/59 PTC T1 10,0 
12 F/39 PTC + NT T1a 0,91 
13 F/28 PTC T2b 1,18 
14 M/27 PTC T3 0,69 
15 F/48 PTC + NT T2b 0,28 
16 M/22 PTC + NT T1; N1 0,99 
17 F/55 PTC + NT T3 7,60 
18 F/51 PTC + NT T1a NA 
19 M/21 PTC + NT T4; N1b NA 
20 F/61 PTC + NT T2; N1 NA 
21 M/35 PTC + NT NA NA 
22 M/31 PTC T2; N1 NA 
23 F/47 PTC + NT T2 1,47 
24 F/62 FTC + NT T2b 1,55 
25 F/16 PTC + NT T2b NA 
26 F/17 PTC + NT T2 NA 
27 F/43 PTC + NT T1a; N1 NA 
28 M/32 PTC NA NA 
29 M/65 PTC + NT T2b; N1 0,89 
30 F/38 PTC + NT T2 1,12 
31, 32 F/56, F/47 Graves’ disease 
33, 34 F/62, F/58 Graves’ disease 
35, 36 F/67, M/55 Graves’ disease 
37, 38 F/50, M/60 Graves’ disease 
39, 40 F/42, F/39 Graves’ disease 
T = primary tumour; N = lymph node metastasis; M = metastasis; NA = not
available; tumour size: T1 < 1 cm; T2 1–5 cm; T3 > 5 cm (tumour without
penetration of thyroid capsule); T4 = infiltration through thyroid capsule);
Ta = monocentric; Tb = multicentric. N0 = tumour without metastasis to lymph
nodes; N1 = metastasis to lymph nodes; N1a = ipsilateral metastasis;
N1b = contralateral metastasis; M0 = without distant metastasis; M1 = distant
metastasis. 
BJOC 01-2015 875-880  10/9/01  2:09 pm  Page 876directly electro-transferred onto Immobilon P (Millipore, Bedford
Corp, MA, USA), and these membranes were then blocked with
3% BSA in PBS-3 mM sodium azide for 60 min at room tempera-
ture. Western blots were done by using a 1:500 dilution of anti-
TPO mAb#47 antibody or a 1:1000 dilution anti-TPO rabbit
polyclonal antibody in PBS-0.1% Tween 20 with 3 mM sodium
azide overnight at 4˚C with constant shaking. After washing 3
times for 15 minute in PBS-Tween 20, membranes were incubated
for 60 min at room temperature under shaking with either
immunoaffinity-purified antimouse IgG conjugated to horseradish
peroxidase or immunoaffinity-purified antirabbit IgG conjugated
to horseradish peroxidase (Jackson ImmunoResearch,
Laboratories, Inc, West Grove, PA, USA). After additional 3
washes, the blots were developed with DAB – metal enhanced,




We observed 3 patterns of TPO protein expression. In 8 malignant
tumours the TPO level was very low or undetectable, in 19
samples there was a variable TPO protein level from very low to
almost normal and in 3 there was a high TPO level. Figure 2 shows
the pattern of Fab binding to TPO captured by mAbs in tissues
representative of these 3 groups, adjacent normal tissue and, as a
control, Graves’ thyroid. 
To assess the relative amount of TPO protein expressed in
thyroid cancer tissues, the results of captured highly purified TPO
at concentrations 1.0, 5.0, 10.0 and 25.0 ng well–1 were compared
to the data obtained for cancer tissues. The relative concentration
of TPO in the 30 tumours ranged from much less than 0.5 µ g mg–1
in 8 cases to more than 12.5 µ g mg–1 of the protein in 3 cases. In
the majority of cancerous tissues however, the TPO amount esti-
mated by the method used ranged from 2.5 to 5 µ g mg–1 of micro-
somes protein (data not shown). 
Epitope mapping 
To get a better insight in the characteristics of the TPO antigenic
activity we analysed the relationship between Fab binding to the
TPO and the mAbs used for the antigen capture. We observed a
cross-competitive effect between mAbs and IgGκ Fab for the
binding sites on the TPO molecule in all cases studied. The Fab
binding to TPO showed cross-reactive inhibition dependent on
which mAb was used for TPO capture. A positive relationship of
the Fab binding to TPO was observed, especially when TPO was
captured by mAbs from domain B. The binding of all Fabs reactive
to domain A (126 TP 1, TP 6, TP 7, TP 8, TP 10 and 126 TO 10)
was high, whereas the binding of Fabs reacting with epitopes
located on domain B (126 TP 5, TP 9, TP 13, TP 14, TP 15 and
126 TO 1) was substantially reduced. 
Strong inhibition of the binding of Fabs reacting with epitopes
located on antigenic domain B with TPO immobilized by domain
B mAbs indicated that epitopes for both mAbs and Fabs were
overlapping. This effect was less pronounced when TPO was
bound to mAbs from antigenic domain A. Fabs reacting with
epitopes located on antigenic domain A react predominantly with
antigenic domain A with some cross-reactivity to domain B. When
TPO was bound to mAbs from antigenic domain D (Figure 2) no
competition between mAbs and Fabs was observed. All Fabs,
whether reactive with antigenic domains A or B, bound equally,
indicating that the epitopes of these monoclonal antibodies and the
Fab-binding sites did not overlap each other. The observed differ-
ences in absorbance values were due to variations in Fab affinity
for the TPO. 
The same pattern of reactivity was observed when TPO from
normal and Graves’ thyroid tissues was captured (see Figure 2B
and 2F). However, the cross-competitive effects between mAbs
and Fabs for binding sites on the TPO was less apparent due to the
high quantity of TPO present in hyperfunctioning tissue. 
SDS-PAGE and Western blot analysis 
In order to confirm the presence or absence of TPO in cancerous
and normal tissues observed using the antigen capture method,
TPO was analysed by SDS-PAGE and Western blot. The intensity
of immunostaining of the TPO bands correlated well with the TPO
level detected by the antigen capture method (Figure 3A, B). In
normal and cancerous tissues taken from the same individuals,
TPO bands were highly immunoreactive and well visualized in the
normal, but not in the corresponding cancerous tissue (Figure 3B).
Only 8 of 30 cancer tissues were negative in Western blot with
both antibodies (Figure 3A; patients 10 and 11). In the remaining
22 cancer tissues, the TPO band intensity varied from very slight
to strong immunostaining with mAb#47 as well as with rabbit
polyclonal anti-TPO antibodies. Using identical amounts of
protein allowed measurement of the relative quantity of the TPO
with respect to intensity and size of the TPO band (Figure 3C).
Densitometric evaluation of the blots demonstrated that in
cancerous tissues, the amount of TPO was 3–20 times lower than
in paired normal tissues. 
DISCUSSION 
In the first part of this study, we evaluated the presence or absence
of TPO protein in differentiated thyroid carcinomas and estimated
the approximative amount of the TPO expressed. Solubilized TPO
was captured by the same panel of anti-TPO murine monoclonal
antibodies used by De Micco et al (1991). TPO was undetectable
or barely detected in 8 of 30 differentiated carcinomas as
compared with the normal paired thyroid tissues. Variable TPO
protein content was found in 19 cancer tissues, and in 3 tissues
TPO was present at a high level, comparable to that detected in the
corresponding normal or Graves’ disease tissues. Several groups
have found that one-third of papillary thyroid carcinomas studied
do not express TPO mRNA, and thus lack TPO enzyme (Hoang-
vu et al, 1992; Fabbro et al, 1994; Tanaka et al, 1996). These cases
should not be immunoreactive with either mAbs or Fabs. The
frequency (26.7%) of differentiated thyroid carcinomas with nega-
tive or extremely low TPO level found in our study (albeit with 6
of them still showing a trace of TPO protein by the method used) is
therefore similar to these reports. Others have produced contradic-
tory data, demonstrating similar if not identical TPO mRNA levels
in a series of malignant thyroid tumours and in benign tissues
(Ohta et al, 1991) for reasons which are not clear. 
The level of TPO detected in cancer tissues varied considerably
from normal to virtually absent. Considering the limitations of
antigen capture as a quantitative method, we could only estimate
the relative amount of the TPO present in cancerous tissues, which
TPO in thyroid carcinoma 877
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BJOC 01-2015 875-880  10/9/01  2:09 pm  Page 877ranged from much less than 0.5 µ g to more than 12.5 µ g mg–1 of
microsome proteins, but the majority was around 2.5 µ g mg–1 to
5 µ g mg–1 of the protein. The presence or absence of TPO in
cancerous tissues detected in antigen capture method was
confirmed by SDS-PAGE and Western blot. The immunolabelling
of the TPO bands with mAb#47 demonstrate that mAb#47 epitope
was expressed on the TPO molecule. Immunohistochemical
techniques using monoclonal antibodies generated against native
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Figure 2 The results of Fab binding to TPO captured by a panel of mAbs in representative cancer tissues. Open bars: Fabs 126 TP1 and 126TP7, reactive 
to domain A – (identical patterns were observed for Fabs 126TP6, TP8, TP10 and 126 TO10). Filled bars: Fabs 126TP5 and 126TP15, reactive to domain 
B – (identical patterns were observed for Fabs 126TP 9, TP 13, TP14 and 126TO1). (A) representative results for tumours with very low TPO level; (B) paired
normal tissue; (C, D) representative results for tissues expressing variable TPO protein level; (E) the data of one of 3 cases with a high TPO level expression;
and (F) the results obtained for control Graves’ tissue (for Graves’ thyroid tissues experiments data presented are mean ± SD). Solid phase coated mAb were
used for TPO capture and Fab in solution used for TPO detection. See Material and Methods for experimental details 
BJOC 01-2015 875-880  10/9/01  2:09 pm  Page 878human TPO have also been frequently used to demonstrate vari-
able levels of TPO protein in thyroid follicular cells under various
pathological conditions, including a large series of malignant
thyroid tumours (DeMicco et al, 1991; Yamashita et al, 1993;
Mizukami et al, 1994; Tanaka et al, 1996). The results of
immunohistochemical methods also differ substantially. Using
immunostaining with 2 (mAb#30 and mAb#47) of 13 mAbs
against native human TPO, De Micco et al (1991) demonstrated
differences in TPO immunoreactivity between benign and malig-
nant tumours and, on this basis, mAb#47 has been proposed as a
specific marker of malignancy. These and other data reported by
this group suggest that although the TPO molecule is present in
thyroid cancers at low levels, the epitope recognized by mAb#47
is not (DeMicco et al, 1991, 1994; Faroux et al, 1997; Garcia et al,
1998). 
To detect any modifications or abnormalities of the TPO mole-
cule expressed in thyroid carcinomas, we chose a structural
approach of mapping the antigenic surface with a panel of 13 well
characterized mAbs directed against native human TPO, and a
panel of human anti-TPO IgGκ Fab fragments (Ruf et al, 1989;
McIntosh et al, 1997). TPO purified from Graves’ tissues was
previously used to map the interaction of a panel of 13 mouse
mAbs to 4 antigenic domains of TPO (Ruf et al, 1989). Human
monoclonal autoantibodies expressed as IgGκ Fab fragments
recognized exclusively epitopes located in only 2 of the 4
domains, A and B (Czarnocka et al, 1997). Moreover, there was no
overlap between the epitopes recognized by the panel of TPO-
specific IgGκ Fab and the epitopes of mAbs reacting with anti-
genic domains C and D (Czarnocka et al, 1997). We observed that
the TPO protein present in cancer tissues did not show any differ-
ences from normal in its antigenic activity, as TPO was captured
by all murine anti-TPO monoclonal antibodies used. Immobilized
TPO showed similar reactivity towards human IgGκ Fabs, with
clearly pronounced steric hindrance dependent on which mAb was
used to capture the TPO. 
The occupancy of the TPO surface by the mAbs reactive to anti-
genic domains A or B inhibited the reactivity of the Fabs with
captured TPO. This was clearly seen when TPO was bound via
mAbs directed to epitopes located on antigenic domain B, indi-
cating that both mAbs and Fabs recognize overlapping part of
TPO. No cross-inhibition of Fab binding to TPO was observed
when TPO was captured by mAbs reactive with antigenic domain
D. This TPO region is not recognized by autoantibodies, and none
of the binding of the recombinant human IgGκ Fabs used was influ-
enced by the occupancy of those mAb epitopes on the TPO mole-
cule (Czarnocka et al, 1997; McIntosh et al, 1997). This result
therefore indicates that, when expressed, TPO in differentiated
thyroid cancer tissues does not differ from TPO in normal thyroid
tissue or Graves’ tissue. TPO in the majority of the cancer tissues
studied was also efficiently captured by mAb#47 with the exception
of the 8 negative cases. From our present study, it is evident that
although the TPO protein in the majority of differentiated thyroid
cancer cases is lower than normal it has unchanged antigenic
activity, when compared to that observed in normal and Graves’
disease tissues. Recently, the correlation of TPO immunostaining by
mAb#47 with the differentiation and proliferative potential of
follicular tumours was examined and a significant correlation
between TPO mAb#47 staining and the proliferating cell nuclear
antigen index with malignancy was found, suggesting that an alter-
ation of TPO antigenicity is an early marker of thyroid follicular
tumours, closely related to tumour growth in the first stages o
TPO in thyroid carcinoma 879
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Figure 3 Western blot analysis of TPO in thyroid cancer tissue after 
SDS-PAGE separation of microsome proteins (20 µ g lane–1) under reducing
conditions probed with anti-TPO mAb#47. (A) Results representative of
cancer tissues; (B) 3 representative cancer tissues and corresponding
normal thyroid tissue; (C) scannergrams comparing the density of the TPO
bands shown in (B). The position of TPO bands are shown by arrows; the
molecular masses of standards are on the left. Papillary thyroid carcinoma (c),
corresponding normal paired tissue (n), Graves’ disease thyroid tissue (G). 
BJOC 01-2015 875-880  10/9/01  2:09 pm  Page 879malignant transformation (Garcia et al, 1998). We found in our series
of malignant thyroid carcinoma tissues a graded expression of TPO
protein from negative to almost normal. However, regardless of any
differences in TPO content, its activity towards both mAbs and Fabs
was similar to observed in normal or Graves’ disease tissues. 
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